

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 7th Floor Conference Rooms
Richmond, VA 23219
April 28, 2016 – 10 AM

Welcome and Comments

Cindi Jones, Director

Call to Order

Tim Jennings, Pharm.D, Chair

Drug Utilization Review (DUR) Board Report

Avtar Dhillon, M.D., DMAS DUR Board

Magellan Medicaid Administration Update

Debbie Moody, RPh, Clinical Manager

Approval of Minutes from October 16, 2015 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

- **PDL Phase I – New Drug Review (*Therapeutic Class*)**
 - Dutasteride/tamsulosin and dutasteride generic - for Jalyn[®] and Avodart[®] (*BPH Agents*)
 - Molindone - generic for Moban[®] (*Antipsychotics*)
 - Olopatadine - generic for Patanol[®] (*Ophthalmics For Allergic Conjunctivitis*)
 - Tobramycin Pak - generic for Kitabis[™] (*Antibiotics, Inhaled*)
 - Upravi[®] (*PAH Agents, Oral & Inhaled*)
 - Utibron[™] Neohaler[®] and Seebri[™] Neohaler[®] (*COPD*)
 - Varubi[™] (*Antiemetics/Antivertigo Agents*)
 - Viberzi[™] (*GI Motility, Chronic*)

- **PDL Phase II – Annual Review (*Therapeutic Class*)**
 - ***Analgesics***
 - § Antimigraine Agents (*formerly in CNS therapeutic class*)
 - § Narcotics: Long Acting
 - § Narcotics: Short Acting (*includes combinations, and lozenges*)
 - § Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (*includes Cox-2 inhibitors and topical agents*)
 - § Opioid Analgesics & Dependency

 - ***Antibiotics/Anti-Infectives***
 - § Antibiotics (*topical*)
 - § Antifungals (*oral*)
 - § Cephalosporins (*Second and Third Generations*)
 - § Gastrointestinal
 - § Ketolides & Macrolides (*Adult and Pediatric*)
 - § Quinolones (*Second and Third Generations*)
 - § Quinolones (*otic*)

 - ***Antivirals***
 - § Antivirals for Herpes
 - § Antivirals for Influenza
 - § Hepatitis C Agents

 - ***Blood Modifiers***
 - § Antihyperuricemics (*previously in Endocrine and Metabolic therapeutic class*)
 - § Erythropoiesis Stimulating Proteins (*previously in Endocrine and Metabolic therapeutic class*)

PDL Phase II – Annual Review (*continued*)

- **Cardiac Medications**
 - § Anticoagulants (*includes oral agents, low molecular weight heparins and Factor XA Inhibitors*)
 - § Platelet Aggregation Inhibitors

- **Central Nervous System**
 - § Antihyperkinesia/CNS Stimulants
 - § Multiple Sclerosis Agents (*previously in Immunological Agents therapeutic class*)
 - § Non-Ergot Dopamine Receptor Agonists
 - § Neuropathic Pain (*previously part of Topical Agents & Anesthetics therapeutic class*)
 - § Skeletal Muscle Relaxants
 - § Smoking Cessation Agents

- **Dermatologic Agents (Topical)**
 - § Acne Agents (*includes benzoyl peroxide, clindamycin, retinoids & combinations*)
 - § Antifungal Agents
 - § Antivirals (*previously in Antiviral therapeutic class*)
 - § Psoriasis Agents

- **Endocrine and Metabolic Agents**
 - § Androgenic Agents
 - § Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonins and others*)
 - § Contraceptives (*oral, vaginal and transdermal*)
 - § Estrogens (*vaginal and oral*)
 - § Hypoglycemics: Alpha-Glucosidase Inhibitors
 - § Hypoglycemics: Incretin-Mimetics/Enhancers (*includes DPPIV*)
 - § Hypoglycemics: Insulins
 - § Hypoglycemics: Meglitinides
 - § Hypoglycemics: Metformins
 - § Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
 - § Hypoglycemics: Sulfonylureas
 - § Hypoglycemics: Thiazolidinediones
 - § Pancreatic Enzymes
 - § Progestational Agents

- **Immunologic Agents**
 - § Self-administered Cytokine & CAM Antagonists with Related Agents (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS) (Immunological Agents)*)

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II Drugs

P&T Committee Members

Next Meeting – October 20, 2016 (tentative)

Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information**

published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – April 2015 to present
- New Drugs in PDL Phase I Drug Classes – April 2014 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on **Thursday, March 24, 2016.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST **Thursday, March 24, 2016.**

DRAFT